Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Asahi Intecc (7747 JP): Well-Positioned to Meet FY Guidance; Long-Term Growth Levers Intact

Asahi Intecc (7747 JP): FY26 Ends on Strong Note; FY27 Guidance Initiation; MTM Plan Revised Upward

Asahi Intecc (7747 JP): Softer H2 Expected; Positive Long-Term Outlook Amid Tariff Noises

Asahi Intecc (7747 JP): Medical Division Drives 9M Result; FY25 Guidance Raised; Buyback Announced

Asahi Intecc (7747 JP): Strong FY25 Result; FY26 Guidance Initiation; New Business Plan Announced

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> has reported strong financial results for H1FY26, with accelerated double-digit growth in key parameters including revenue, operating profit, and net profit.</li>
<li>Revenue from medical division increased 12% YoY to ¥63B. Asahi’s mainstay cardiovascular business performed well in all the regions, with PCI guidewire and penetration catheter seeing strong demand.</li>
<li>Amid expanding demand and better-than-expected foreign exchange rates, Asahi Intecc has revised FY26 guidance upward. The company expects FY26 revenue growth of 18% and operating profit growth of 40%.</li>
</ul>



Asahi Intecc (7747 JP) has reported strong financial results for H1FY26, with accelerated double-digit growth in key parameters including revenue, operating profit, and net profit.
Revenue from medical division increased 12% YoY to ¥63B. Asahi’s mainstay cardiovascular business performed well in all the regions, with PCI guidewire and penetration catheter seeing strong demand.
Amid expanding demand and better-than-expected foreign exchange rates, Asahi Intecc has revised FY26 guidance upward. The company expects FY26 revenue growth of 18% and operating profit growth of 40%.


Asahi Intecc (7747 JP): Strong Demand Drives H1FY26 Performance and FY26 Guidance Raise